Share Prices & Company Research

Stockbroking

AstraZeneca

Current Price 6376.00p Bid 6373.00p Ask 6376.00p Change 0.00%
Last Updated: 26/03/2019 04:59. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

AstraZeneca plc is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Financial Highlights Year Ended 31/12/2018

Turnover
£22,090.00m
Operating Profit
£3,387.00m
Dividend Yield
3.33
Dividend Per Share
215.20
Dividend Cover
0.79
P/E Ratio
38.00

Key Personnel

Pascal Claude Roland Soriot
Chief Executive Officer
Marc Pierre Jean Dunoyer
Chief Financial Officer
Leif Valdemar Johansson
Non-Executive Chairman
Tony Shu Kam Mok
Non-Executive Director
Marcus Wallenberg
Non-Executive Director
Rudolph Harold Peter Markham
Non-Executive Director
Prof Sabera Nazneen Rahman
Non-Executive Director
Sherilyn Dawn McCoy
Non-Executive Director
Deborah DiSanzo
Non-Executive Director
Graham Andrew Chipchase
Non-Executive Director
Philip Arthur John Broadley
Non-Executive Director
Prof Geneviève Bernadette Berger
Non-Executive Director

Stock Details

EPIC
AZN
ISIN
GB0009895292
Shares in Issue
1,267,287,658
Market cap
£81,860.45m

Analyst Views (10)

Strong Buy
 
50.00%
Buy
 
0.00%
Hold
 
40.00%
Sell
 
0.00%
Strong Sell
 
10.00%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
0.00p
Bid Price
6373.00p
Ask Price
6376.00p
Volume
0
Change Today
0.00p
% Change Today
0.00%
Open
0.00p
Previous Close
6376.00p
Intraday High
0.00p
Intraday Low
0.00p
52 Week High
6540.00p
52 Week Low
4746.00p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

AstraZeneca Intra-day Chart

AstraZeneca News

News in this section is provided by AJ Bell

AstraZeneca's oral diabetes treatment gets European regulatory approval 25 Mar 2019 | 07:23 FTSE gains as sterling weakens on potential Brexit setback 18 Mar 2019 | 17:00 UK stocks hold on to gains by midday as investors await big news 18 Mar 2019 | 12:13 Astrazeneca's lung disease treatment granted orphan drug status in US 18 Mar 2019 | 07:42 Broker Forecast - Goldman Sachs issues a broker note on AstraZeneca PLC 12 Mar 2019 | 13:10 AstraZeneca, Merck breast cancer treatment gets EU regulatory nod 01 Mar 2019 | 15:11 AstraZeneca, Merck reveal positive results from pancreatic cancer treatment 26 Feb 2019 | 08:58 AstraZeneca heart treatment effective during trial 25 Feb 2019 | 16:16 Broker Forecast - Bryan Garnier issues a broker note on AstraZeneca PLC 22 Feb 2019 | 10:50 Pound weakens as another Brexit vote looms 14 Feb 2019 | 16:50 Strong earnings and trade hopes push FTSE above 7,200 14 Feb 2019 | 12:13 UK stocks edge higher ahead of fresh Brexit debates 14 Feb 2019 | 09:42 AstraZeneca meets guidance as strong performance of new medicines deliver boost 14 Feb 2019 | 07:28 FTSE 100 fails to gain momentum 06 Feb 2019 | 17:05 Weakness in utility stocks hits FTSE 06 Feb 2019 | 12:11 UK stocks open 0.3% lower as Brexit uncertainty weighs 06 Feb 2019 | 09:01 AstraZeneca treatment for hypereosinophilic syndrome granted orphan status 06 Feb 2019 | 08:19 Global equities gain momentum despite weak European services data 05 Feb 2019 | 16:55 FTSE gains momentum on BP beat and weaker sterling 05 Feb 2019 | 12:02 UK stocks open 0.9% stronger, buoyed by BP beat 05 Feb 2019 | 09:04 AstraZeneca's respiratory tract infection treatment receives favourable status from European and US health authorities 05 Feb 2019 | 07:52 AstraZeneca gets European regulatory nod for oral diabetes treatment 01 Feb 2019 | 13:59 AstraZeneca completes sale of respiratory tract treatment to Sobi for $1.6bn 25 Jan 2019 | 14:06 Broker Forecast - Shore Capital issues a broker note on AstraZeneca PLC 25 Jan 2019 | 10:50 Broker Forecast - Societe Generale issues a broker note on AstraZeneca PLC 16 Jan 2019 | 11:30 AstraZeneca hires new oncology R&D head amid organisational revamp 07 Jan 2019 | 13:38 FTSE falls as UK growth forecasts lowered 20 Dec 2018 | 16:41 FTSE recovers some ground after early fall 20 Dec 2018 | 11:59 UK stocks fall after Wednesday's US rate hike 20 Dec 2018 | 09:32 AstraZeneca's chronic kidney disease treatment meets primary objectives 20 Dec 2018 | 07:34

Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Tangible Assets
7,421.0
7,615.0
Intangible Assets & Goodwill
33,666.0
38,013.0
Investments & Other Non-Current Assets
3,973.0
4,576.0
Total Non-Current Assets
45,060.0
50,204.0
Inventory
2,890.0
3,035.0
Trade & Receivables
5,574.0
5,009.0
Cash & Receivables
4,831.0
3,324.0
Other Current Assets & Assets Held for Resale
2,296.0
1,782.0
Total Assets
60,651.0
63,354.0

Liabilities (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Short Term Liabilities
16,292.0
16,383.0
Long Term Liabilities
30,315.0
30,329.0
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
46,607.0
46,712.0

Net Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Net Assets
14,044.0
16,642.0

Equity (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Share Capital
317.0
317.0
Minority Interests
1,576.0
1,682.0
Retained Earnings
5,683.0
8,221.0
Share Premium Account
4,427.0
4,393.0
Other Equity
2,041.0
2,029.0
Total Equity
14,044.0
16,642.0

Cashflow (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Cashflow from Operating Activities
2,618.0
3,578.0
Cashflow Before Financing
3,581.0
1,250.0
Increase / Decrease in Cash
1,537.0
-1,686.0

Income (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Turnover
22,090.0
22,465.0
Cost of Sales
4,936.0
4,318.0
Gross Profit
17,154.0
18,147.0
Operating Profit
3,387.0
3,677.0
Pre-Tax Profit
1,993.0
2,227.0
Profit / Loss for the Year
2,050.0
2,868.0

Dividend History

Data has been provided by AJ Bell

Period
Ex-Dividend Date
Payment Date
H2 Dividend
28 Feb 2019
27 Mar 2019
H1 Dividend
09 Aug 2018
10 Sep 2018
H2 Dividend
15 Feb 2018
19 Mar 2018
H1 Dividend
10 Aug 2017
11 Sep 2017
H2 Dividend
16 Feb 2017
20 Mar 2017
H1 Dividend
11 Aug 2016
12 Sep 2016
H2 Dividend
18 Feb 2016
21 Mar 2016
H1 Dividend
13 Aug 2015
14 Sep 2015
H2 Dividend
19 Feb 2015
23 Mar 2015
H1 Dividend
13 Aug 2014
15 Sep 2014
H2 Dividend
19 Feb 2014
24 Mar 2014
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.